209 related articles for article (PubMed ID: 11052625)
1. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
[TBL] [Abstract][Full Text] [Related]
2. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
[TBL] [Abstract][Full Text] [Related]
6. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
7. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
[TBL] [Abstract][Full Text] [Related]
8. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
[TBL] [Abstract][Full Text] [Related]
9. [Immobilized forms of daunorubicin in patients with acute leukemia].
Isaev VG; Garmaeva TTs; Skorokhod AA; Parovichnikova EN; Tiurina NG; Kucher RA; Vitvitskiĭ VM; Ataullakhanov FI; Savchenko VG
Ter Arkh; 1999; 71(10):32-7. PubMed ID: 10612171
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
11. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
Michieli M; Damiani D; Ermacora A; Masolini P; Michelutti A; Michelutti T; Russo D; Pea F; Baccarani M
Br J Haematol; 1999 Jul; 106(1):92-9. PubMed ID: 10444168
[TBL] [Abstract][Full Text] [Related]
13. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of liposomal daunorubicin in children.
Hempel G; Reinhardt D; Creutzig U; Boos J
Br J Clin Pharmacol; 2003 Oct; 56(4):370-7. PubMed ID: 12968981
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia].
Sun YN; Chai YH; Xu YJ; Lü H
Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):296-300. PubMed ID: 19555570
[TBL] [Abstract][Full Text] [Related]
16. Liposomal daunorubicin as treatment for Kaposi's sarcoma.
Petre CE; Dittmer DP
Int J Nanomedicine; 2007; 2(3):277-88. PubMed ID: 18019828
[TBL] [Abstract][Full Text] [Related]
17. In vitro sensitivity to the liposomal preparation, DaunoXome in CLL.
Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
Anticancer Res; 1999; 19(4B):3253-7. PubMed ID: 10652620
[TBL] [Abstract][Full Text] [Related]
18. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
